ビスフォスフォネート医薬品の世界市場レポート 2025年

ビスフォスフォネート医薬品市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は5.9％で、66億6,000万米ドルに成長します。予測期間中に予想される成長の原動力となるのは、ビスフォスフォネート系薬剤のジェネリック医薬品の入手可能性の増加、世界人口の急速な高齢化、骨減少症の発見率の上昇、がんによる骨合併症の急増、規制当局による積極的なガイドライン、予防ヘルスケアの重視の高まりなどです。主要新たな動向としては、経口製剤への嗜好の高まり、ドラッグデリバリーシステムの革新、デジタルツールの利用による患者の取り込み、遺伝子プロファイルによる個別化治療アプローチ、予測的健康モニタリングのためのAI技術の採用などが挙げられます。

骨粗鬆症の罹患率の上昇は、今後数年間のビスフォスフォネート医薬品市場の成長を促進すると予想されます。骨粗鬆症は、骨密度の低下により骨折しやすくなる骨の弱体化を特徴とする疾患です。骨粗鬆症の有病率の増加は、世界人口の高齢化に起因するところが大きく、骨密度は加齢とともに自然に低下するため、生活習慣要因や不十分な予防医療も加わっています。ビスフォスフォネート系薬剤は、骨の分解を遅らせることで骨を強化し、骨折のリスクを下げることで骨粗鬆症を治療します。例えば、2024年8月にHealthy Bones Australiaが発表した報告によると、2023年には骨粗鬆症と骨減少症に関連した骨折が約19万3,482件発生しました。この数は、2033年には34％増の23万7,632人になると予測されています。その結果、骨粗鬆症患者数の増加がビスフォスフォネート医薬品市場の成長に拍車をかけています。

ビスフォスフォネート医薬品市場の主要企業は、製品アクセスを拡大し、市場競合を強化し、進化する安全性と有効性の基準に準拠するために、規制当局の承認を重視しています。規制当局の承認は、政府の保健機関によって付与され、安全性と有効性を確認した上で、企業が医薬品を販売することを許可するものです。例えば、2025年3月、韓国のバイオ医薬品会社であるセルトリオンは、バイオシミラーであるストボクロ（デノスマブ-bmwo）とオセンベルト（デノスマブ-bmwo）の米国FDA承認を取得しました。ストボクロは、閉経後女性と男性の骨粗鬆症、グルココルチコイド誘発性骨粗鬆症、特定のがん治療による骨量減少など、さまざまな骨粗鬆症関連疾患の治療として承認されています。一方、オセンベルトは、多発性骨髄腫または骨転移患者における骨合併症の予防、骨巨細胞腫の治療、悪性腫瘍に伴う高カルシウム血症の管理など、がんに関連する骨格の問題に適応があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のビスフォスフォネート医薬品：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のビスフォスフォネート医薬品市場：成長率分析
• 世界のビスフォスフォネート医薬品市場の実績：規模と成長、2019～2024年
• 世界のビスフォスフォネート医薬品市場の予測：規模と成長、2024～2029年、2034年
• 世界のビスフォスフォネート医薬品：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のビスフォスフォネート医薬品市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アレンドロネート
• リセドロネート
• ゾレドロン酸
• ゾレドロン酸
• 世界のビスフォスフォネート医薬品市場：送達方法別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 静脈内
• 世界のビスフォスフォネート医薬品市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界のビスフォスフォネート医薬品市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 閉経後骨粗鬆症
• 骨粗鬆症の男性
• パジェット病
• がん治療による骨粗鬆症
• グルココルチコイド誘発性骨粗鬆症
• その他
• 世界のビスフォスフォネート医薬品市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 在宅ケア
• その他
• 世界のビスフォスフォネート医薬品市場、アレンドロネートのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口アレンドロン酸錠
• 発泡性アレンドロン酸錠
• アレンドロン酸処方薬
• ジェネリックアレンドロネート
• ブランド名アレンドロン酸
• 世界のビスフォスフォネート医薬品市場、リセドロネートのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 即放性リセドロネート錠
• 遅延放出リセドロネート錠
• リセドロネート処方薬
• ジェネリックリセドロネート
• ブランド名リセドロネート
• 世界のビスフォスフォネート医薬品市場、ゾレドロン酸のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ゾレドロン酸静脈内投与
• 単回投与点滴
• 複数回投与レジメン
• ジェネリックゾレドロン酸
• ブランドゾレドロン酸
• 世界のビスフォスフォネート医薬品市場、ゾレドロン酸のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• イバンドロネート（経口と静脈内投与）
• エチドロン酸
• パミドロン酸
• チルドロネート
• 実験的またはパイプラインのビスホスホネート

第7章 地域別・国別分析

• 世界のビスフォスフォネート医薬品市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のビスフォスフォネート医薬品市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ビスフォスフォネート医薬品市場：競合情勢
• ビスフォスフォネート医薬品市場：企業プロファイル
  • Pfizer Inc.
  • Roche Holding AG
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Bayer AG

第31章 その他の大手企業と革新的企業

• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries
• Sun Pharmaceutical Industries Ltd.
• Apotex Inc.
• Aurobindo Pharma Ltd
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Hikma Pharmaceuticals
• Zydus Lifesciences Ltd.
• Alkem Laboratories
• Natco Pharma Ltd.
• Strides Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• ビスフォスフォネート医薬品市場、2029年：新たな機会を提供する国
• ビスフォスフォネート医薬品市場、2029年：新たな機会を提供するセグメント
• ビスフォスフォネート医薬品市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Bisphosphonates are a class of medications that help prevent bone density loss. They are widely prescribed to manage or prevent osteoporosis and other bone-related conditions by inhibiting the processes that lead to bone degradation. The primary goal of bisphosphonates is to enhance bone strength and lower the risk of fractures, particularly in patients diagnosed with osteoporosis.

The principal types of bisphosphonate medications include alendronate, risedronate, and zoledronic acid. Alendronate is commonly used to prevent and treat osteoporosis by reducing bone resorption and promoting bone mass gain. These drugs are available in both oral and intravenous formulations and are distributed through hospital pharmacies, retail outlets, online pharmacies, and other channels. They are used for various indications, such as postmenopausal osteoporosis, male osteoporosis, Paget's disease, cancer therapy-induced bone loss, glucocorticoid-induced osteoporosis, and more. The end users of these drugs include hospitals, clinics, home care environments, and other healthcare settings.

The bisphosphonate drug market research report is one of a series of new reports from The Business Research Company that provides bisphosphonate drug market statistics, including bisphosphonate drug industry global market size, regional shares, competitors with a bisphosphonate drug market share, detailed bisphosphonate drug market segments, market trends and opportunities, and any further data you may need to thrive in the bisphosphonate drug industry. This bisphosphonate drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bisphosphonate drug market size has grown strongly in recent years. It will grow from $4.98 billion in 2024 to $5.28 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. This expansion during the historical period was fueled by the rising incidence of osteoporosis, greater public awareness regarding bone health, widespread usage of drugs like alendronate and risedronate, a growing demographic of postmenopausal women, and increased demand for therapies related to bone cancer and metastasis.

The bisphosphonate drug market size is expected to see strong growth in the next few years. It will grow to $6.66 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth during the forecast period will be driven by the increased availability of generic bisphosphonates, a rapidly aging global population, higher detection rates of osteopenia, a surge in bone complications from cancer, proactive guidelines from regulatory bodies, and a heightened emphasis on preventive healthcare. Key emerging trends include the growing preference for oral formulations, innovations in drug delivery systems, the use of digital tools to engage patients, personalized treatment approaches based on genetic profiles, and the adoption of AI technologies for predictive health monitoring.

The rising incidence of osteoporosis is expected to drive the growth of the bisphosphonates drug market in the coming years. Osteoporosis is a condition marked by weakened bones that are more susceptible to fractures due to decreased bone density. The growing prevalence of osteoporosis is largely attributed to the aging global population, as bone density naturally declines with age, along with lifestyle factors and inadequate preventive care. Bisphosphonate drugs treat osteoporosis by slowing bone degradation, thereby strengthening bones and lowering the risk of fractures. For example, in August 2024, Healthy Bones Australia reported that in 2023, there were approximately 193,482 fractures associated with osteoporosis and osteopenia. This number is projected to increase by 34% to 237,632 fractures by 2033. As a result, the rising number of osteoporosis cases is fueling the growth of the bisphosphonates drug market.

Leading companies in the bisphosphonate drug market are emphasizing regulatory approvals to expand product access, enhance market competitiveness, and comply with evolving safety and efficacy standards. Regulatory approvals, granted by government health agencies, authorize companies to market and sell their drugs after confirming they are safe and effective. For instance, in March 2025, Celltrion, Inc., a biopharmaceutical firm based in South Korea, received U.S. FDA approval for its biosimilars STOBOCLO (denosumab-bmwo) and OSENVELT (denosumab-bmwo). STOBOCLO is approved for treating various osteoporosis-related conditions, including osteoporosis in postmenopausal women and men, glucocorticoid-induced osteoporosis, and bone loss from specific cancer treatments. OSENVELT, on the other hand, is indicated for cancer-related skeletal issues such as preventing bone complications in patients with multiple myeloma or bone metastases, treating giant cell tumor of bone, and managing malignancy-associated hypercalcemia.

In May 2023, Abiogen Pharma S.p.A., a pharmaceutical company based in Italy, acquired EffRx Pharmaceuticals SA for an undisclosed sum. This acquisition was aimed at strategically strengthening and diversifying Abiogen's rare disease portfolio by incorporating EffRx's innovative treatments for musculoskeletal and rare disorders. It also helps Abiogen expand its international reach and capabilities in developing and commercializing specialized therapies globally. EffRx Pharmaceuticals SA, located in Switzerland, is a specialty pharmaceutical firm that produces and markets bisphosphonate drugs for osteoporosis treatment.

Major players in the bisphosphonate drug market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries, Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Hikma Pharmaceuticals, Zydus Lifesciences Ltd., Alkem Laboratories, Natco Pharma Ltd., Strides Pharma, Radius Health Inc., EffRx Pharmaceuticals, Warner Chilcott, and Abiogen Pharma S.p.A.

North America was the largest region in the bisphosphonate drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bisphosphonate drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bisphosphonate drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bisphosphonate drug market consists of sales of products including oral tablets, bisphosphonate capsules, bisphosphonate injections, oral solutions, and intravenous (IV) infusions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bisphosphonate Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bisphosphonate drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bisphosphonate drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bisphosphonate drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Alendronate; Risedronate; Zoledronic Acid; Zoledronic Acid
• 2) By Mode Of Delivery: Oral; Intravenous
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 4) By Application: Postmenopausal Osteoporosis; Men With Osteoporosis; Paget's Disease; Bone Loss Caused By Cancer Treatment; Glucocorticoid Induced Osteoporosis; Other Applications
• 5) By End User: Hospitals; Clinics; Homecare Settings; Other End Users
• Subsegments:
• 1) By Alendronate: Oral Alendronate Tablets; Effervescent Alendronate Tablets; Alendronate Combination Drugs; Generic Alendronate; Branded Alendronate
• 2) By Risedronate: Immediate-Release Risedronate Tablets; Delayed-Release Risedronate Tablets; Risedronate Combination Drugs; Generic Risedronate; Branded Risedronate
• 3) By Zoledronic Acid: Intravenous Zoledronic Acid; Single-Dose Infusion; Multiple-Dose Regimens; Generic Zoledronic Acid; Branded Zoledronic Acid
• 4) By Other Types: Ibandronate (Oral And IV Forms); Etidronate; Pamidronate; Tiludronate; Experimental Or Pipeline Bisphosphonates
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bisphosphonate Drug Market Characteristics

3. Bisphosphonate Drug Market Trends And Strategies

4. Bisphosphonate Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Bisphosphonate Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bisphosphonate Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bisphosphonate Drug Market Growth Rate Analysis
• 5.4. Global Bisphosphonate Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bisphosphonate Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bisphosphonate Drug Total Addressable Market (TAM)

6. Bisphosphonate Drug Market Segmentation

• 6.1. Global Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alendronate
• Risedronate
• Zoledronic Acid
• Zoledronic Acid
• 6.2. Global Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• 6.3. Global Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Bisphosphonate Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Postmenopausal Osteoporosis
• Men With Osteoporosis
• Paget's Disease
• Bone Loss Caused By Cancer Treatment
• Glucocorticoid Induced Osteoporosis
• Other Applications
• 6.5. Global Bisphosphonate Drug Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Homecare Settings
• Other End Users
• 6.6. Global Bisphosphonate Drug Market, Sub-Segmentation Of Alendronate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Alendronate Tablets
• Effervescent Alendronate Tablets
• Alendronate Combination Drugs
• Generic Alendronate
• Branded Alendronate
• 6.7. Global Bisphosphonate Drug Market, Sub-Segmentation Of Risedronate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate-Release Risedronate Tablets
• Delayed-Release Risedronate Tablets
• Risedronate Combination Drugs
• Generic Risedronate
• Branded Risedronate
• 6.8. Global Bisphosphonate Drug Market, Sub-Segmentation Of Zoledronic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Zoledronic Acid
• Single-Dose Infusion
• Multiple-Dose Regimens
• Generic Zoledronic Acid
• Branded Zoledronic Acid
• 6.9. Global Bisphosphonate Drug Market, Sub-Segmentation Of Zoledronic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibandronate (Oral And IV Forms)
• Etidronate
• Pamidronate
• Tiludronate
• Experimental Or Pipeline Bisphosphonates

7. Bisphosphonate Drug Market Regional And Country Analysis

• 7.1. Global Bisphosphonate Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bisphosphonate Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bisphosphonate Drug Market

• 8.1. Asia-Pacific Bisphosphonate Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bisphosphonate Drug Market

• 9.1. China Bisphosphonate Drug Market Overview
• 9.2. China Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bisphosphonate Drug Market

• 10.1. India Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bisphosphonate Drug Market

• 11.1. Japan Bisphosphonate Drug Market Overview
• 11.2. Japan Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bisphosphonate Drug Market

• 12.1. Australia Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bisphosphonate Drug Market

• 13.1. Indonesia Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bisphosphonate Drug Market

• 14.1. South Korea Bisphosphonate Drug Market Overview
• 14.2. South Korea Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bisphosphonate Drug Market

• 15.1. Western Europe Bisphosphonate Drug Market Overview
• 15.2. Western Europe Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bisphosphonate Drug Market

• 16.1. UK Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bisphosphonate Drug Market

• 17.1. Germany Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bisphosphonate Drug Market

• 18.1. France Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bisphosphonate Drug Market

• 19.1. Italy Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bisphosphonate Drug Market

• 20.1. Spain Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bisphosphonate Drug Market

• 21.1. Eastern Europe Bisphosphonate Drug Market Overview
• 21.2. Eastern Europe Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bisphosphonate Drug Market

• 22.1. Russia Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bisphosphonate Drug Market

• 23.1. North America Bisphosphonate Drug Market Overview
• 23.2. North America Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bisphosphonate Drug Market

• 24.1. USA Bisphosphonate Drug Market Overview
• 24.2. USA Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bisphosphonate Drug Market

• 25.1. Canada Bisphosphonate Drug Market Overview
• 25.2. Canada Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bisphosphonate Drug Market

• 26.1. South America Bisphosphonate Drug Market Overview
• 26.2. South America Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bisphosphonate Drug Market

• 27.1. Brazil Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bisphosphonate Drug Market

• 28.1. Middle East Bisphosphonate Drug Market Overview
• 28.2. Middle East Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bisphosphonate Drug Market

• 29.1. Africa Bisphosphonate Drug Market Overview
• 29.2. Africa Bisphosphonate Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bisphosphonate Drug Market, Segmentation By Mode Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bisphosphonate Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bisphosphonate Drug Market Competitive Landscape And Company Profiles

• 30.1. Bisphosphonate Drug Market Competitive Landscape
• 30.2. Bisphosphonate Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Bisphosphonate Drug Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Viatris Inc.
• 31.5. Teva Pharmaceutical Industries
• 31.6. Sun Pharmaceutical Industries Ltd.
• 31.7. Apotex Inc.
• 31.8. Aurobindo Pharma Ltd
• 31.9. Dr. Reddy's Laboratories Ltd.
• 31.10. Cipla Ltd.
• 31.11. Hikma Pharmaceuticals
• 31.12. Zydus Lifesciences Ltd.
• 31.13. Alkem Laboratories
• 31.14. Natco Pharma Ltd.
• 31.15. Strides Pharma

32. Global Bisphosphonate Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bisphosphonate Drug Market

34. Recent Developments In The Bisphosphonate Drug Market

35. Bisphosphonate Drug Market High Potential Countries, Segments and Strategies

• 35.1 Bisphosphonate Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bisphosphonate Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bisphosphonate Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer